Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis

Abstract

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS, the public...

Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.

“…The utilities for AP and blast phase reported by Reed et al 116 are slightly different from those quoted by Dalziel et al, 65 although both are taken from the IRIS trial originally. 26,116,130 In the Reed et al analysis, 116 no difference was assumed between AP and blast phase, as the observed difference in values was not statistically significant.…”

“…These data were collected for patients taking imatinib during the IRIS trial, 26 as reported by Reed et al 116 and used by Dalziel et al 65 in a previous HTA of imatinib for CML. These data are drawn from a large sample of patients, using the EQ-5D, which is preferred in the NICE reference case.…”

Hematopoietic stem cell transplants for chronic myeloid leukemia in Europe—Impact of cost considerations

“…Cost comparisons with imatinib have shown favorable results in the US. 23,24 These findings appear not to apply in all countries.…”

Predictability of hematopoietic stem cell transplantation rates

“…It is highly likely that such considerations will have an even stronger impact in the future for countries in the middle income category when modern expensive therapies such as iron chelation in thalassemia or antibody treatment in paroxysmal nocturnal hemoglobinuria will have to be compared with HSCT. [21][22][23][24][25][26][27] Our analysis has some limitations. Firstly, there is no uniform database on the incidence or prevalence of the individual disease categories in European countries.…”